Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

approvedPositive

AI Analysis

Summary

Fresenius has completed its acquisition of mAbxience, gaining full ownership of the biosimilar company to strengthen its platform for portfolio expansion and enhance supply resilience.

Outcome Details

Fresenius completed full acquisition of mAbxience

Importance:7/10

Sentiment:

0.60

M&Abiosimilarsacquisitionsupply chain

Related Companies

$FMCQF

Read the original article

Published by PR Newswire Biotech on October 1, 2026 5:00 AM

Read Original